BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
BRAF V600E expression in histiocytic sarcoma associated with splenic marginal zone lymphoma: a case report ; volume:11 ; number:1 ; day:5 ; month:4 ; year:2017 ; pages:1-4 ; date:12.2017
Journal of medical case reports ; 11, Heft 1 (5.4.2017), 1-4, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Vaughn, John L.
- Beteiligte Personen und Organisationen
-
Freitag, C. Eric
Hemminger, Jessica A.
Jones, Jeffrey A.
SpringerLink (Online service)
- DOI
-
10.1186/s13256-017-1253-z
- URN
-
urn:nbn:de:1111-201704138099
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:46 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Vaughn, John L.
- Freitag, C. Eric
- Hemminger, Jessica A.
- Jones, Jeffrey A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
BRAF-V600E-Testung beim metastasierten kolorektalen Karzinom und neue, chemotherapiefreie Therapieoptionen
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate
BRAF-V600E-Testung beim metastasierten kolorektalen Karzinom und neue, chemotherapiefreie Therapieoptionen
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
Validierung eines Protokolls zur manuellen, mutationsspezifischen BRAF V600E Immunhistochemie
Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis
BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF V600E colorectal cancer
Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF V600E metastatic colorectal cancer
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
Frequency of BRAF V600E mutations in 969 central nervous system neoplasms
BRAF V600E-Positive Multisite Langerhans Cell Histiocytosis in a Preterm Neonate